Gastrointestinal Cancer

>

Latest News

Updated Data and Groundbreaking Research Lead to an Exciting 2023 ASCO GI
Updated Data and Groundbreaking Research Lead to an Exciting 2023 ASCO GI

March 29th 2023

Co-editor-in-Chief Howard S. Hochster, MD, highlights the most exciting developments from the 2023 Gastrointestinal Cancer Symposium hosted by the American Society of Clinical Oncology (ASCO).

National Comprehensive Cancer Network guidelines will now include ripretinib as the ideal second-line treatment for patients with unresectable/metastatic gastrointestinal stromal tumors who are intolerant to sunitinib.
Ripretinib Receives FDA BTD for KIT+ Gastrointestinal Stromal Tumors

March 16th 2023

ODAC Votes 8-5 in Favor of Dostarlimab Trial in Advanced Rectal Cancer
ODAC Votes 8-5 in Favor of Dostarlimab Trial in Advanced Rectal Cancer

February 9th 2023

Data from the final analysis of the phase 3 KEYNOTE-966 trial indicate that pembrolizumab plus chemotherapy yield improvements in overall survival compared with chemotherapy alone in patients with advanced biliary tract cancer.
Pembrolizumab/Chemo Improves Survival Vs Chemo Alone in Biliary Tract Cancer

February 2nd 2023

An expert from the Smilow Cancer Hospital and Yale Cancer Center indicates that findings from the ctDNA analysis of the phase 3 INTRIGUE study were “provocative” and the subsequent phase 3 INSIGHT study has the potential to be practice changing should data be positive.
KIT Mutational Status Correlates With Response in Advanced GIST

January 25th 2023

More News